Bausch + Lomb Corporation Q1 2026 Financial Report: Key Investor Insights

Overview

Bausch + Lomb Corporation (“Bausch + Lomb” or “the Company”) has released its Form 10-Q for the quarterly period ended March 31, 2026. The report contains detailed financial statements, forward-looking statements, and risk disclosures that are essential for investors and shareholders.

Key Financial Highlights

• Revenues: For Q1 2026, product sales revenue was \$1,137 million, slightly higher than the prior year’s \$1,126 million, indicating modest year-on-year growth.
• Cash and Cash Equivalents: The company had \$268 million in cash and cash equivalents as of March 31, 2026, compared to \$383 million at the end of 2025, signaling a decrease in liquidity this quarter.
• Total Assets: Bausch + Lomb reported total assets of \$13,780 million at the end of Q1 2026, down from \$14,022 million at year-end 2025.
• Shareholder Equity: Shareholders’ equity stood at \$6,379 million as of March 31, 2026, a decrease from \$6,448 million at December 31, 2025.
• Shares Outstanding: Common shares outstanding as of April 22, 2026 were 356,536,358.
• R&D and SG&A Expenses: Research and development expense was \$101 million (up from \$86 million), and Selling, General and Administrative (SG&A) expenses were \$563 million (up from \$543 million), highlighting increased spending in both areas.
• Accumulated Deficit: The company reported an accumulated deficit of \$1,002 million, slightly higher than the prior quarter’s \$931 million.
• Accumulated Other Comprehensive Loss: This stood at \$1,199 million, up from \$1,175 million, indicating increased losses in this category.

Forward-Looking Statements & Risks

The company provided extensive forward-looking statements, cautioning investors regarding potential risks and uncertainties. Key risks and factors include:

• Macroeconomic Environment: Adverse economic conditions, inflation, interest rates, and currency fluctuations could impact revenues and margins.
• Separation from Bausch Health Companies Inc. (BHC): The proposed separation from BHC is a major strategic move. The timing, structure, and benefits of this separation are uncertain, and any delays or failure to execute could significantly affect shareholder value.
• Regulatory Actions: Actions by the FDA or other regulatory authorities regarding products or manufacturing facilities could materially impact the business.
• Debt and Credit Ratings: Changes in credit ratings may affect the Company’s ability to raise additional debt and the cost of capital.
• Acquisitions and New Products: Risks associated with acquisitions, launch of new products, and integration thereof, including failure to achieve expected benefits or regulatory approvals, may impact financial results.
• Market Competition: Increased competition, industry consolidation, and potential new entrants could affect market share and profitability.
• Legal Proceedings: Potential ongoing or future legal proceedings may impact financials and reputation.
• Information Technology and Cybersecurity: Any breaches or failures could affect operations and financial performance.
• Tax Risks: Changes in tax treaties and effective rates could impact net profits.
• Global Operations: Risks associated with international operations, compliance with laws in emerging markets, and potential sanctions.

The company highlighted that the forward-looking statements are subject to risks detailed in previous filings, especially the Annual Report on Form 10-K for the year ended December 31, 2025.

Shareholder Information & Potential Price Sensitivity

• The proposed separation from BHC remains a major, potentially price-sensitive factor. Investors should monitor developments closely, as any change in strategy, timing, or execution could materially affect share value.
• Increased R&D and SG&A spending may indicate investment in growth, but could also pressure margins if not offset by higher revenues or successful product launches.
• Decreased liquidity (drop in cash and equivalents) may signal increased capital expenditures or acquisition activity, but could also raise concerns about financial flexibility if trends persist.
• Continued accumulation of deficit and comprehensive loss, despite stable revenues, may be viewed negatively unless the Company demonstrates a clear path to profitability and growth.
• The company is not a shell company and is listed on both the NYSE (BLCO) and Toronto Stock Exchange, with current reporting compliance affirmed.

Potential Share Price Drivers

Investors should pay particular attention to:

• Updates on the BHC Separation: Any announcements on timing, structure, or completion could move the share price.
• Regulatory or Legal Developments: FDA actions, litigation results, or changes in the regulatory environment.
• New Product Launches/Acquisitions: Success or failure in these areas can impact future revenue growth and market share.
• Changes in Financial Health: If the cash position continues to decline, or deficits worsen, investor sentiment may be negatively affected.
• Macroeconomic and Geopolitical Factors: Global events, such as the Russia-Ukraine conflict, Middle East unrest, tariffs, and trade restrictions, may impact supply chains and international sales.

Conclusion

Bausch + Lomb Corporation’s Q1 2026 report presents a stable but cautious financial outlook with modest revenue growth, increased operating expenses, and continued strategic uncertainty regarding the separation from BHC. Shareholders and investors should closely monitor developments in separation plans, regulatory actions, and financial health indicators, as these could significantly affect the share price in the coming months.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult official filings and their financial advisors before making any investment decisions. Past performance is not indicative of future results. The author assumes no responsibility for investment losses related to the information herein.

View Bausch & Lomb Corp Historical chart here